Categories: Health

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

GlobeNews Wire

Recent Posts

InFocus launches digital ventures strategy with Mythos Group to push into Blockchain, AI and Bitcoin

SYDNEY, Sept. 1, 2025 /PRNewswire/ -- InFocus Group Holdings Limited (ASX: IFG) (InFocus), a data…

3 hours ago

Bybit Spot Lists WLFI with 1.6 Million WLFI in Prizes

DUBAI, UAE, Sept. 1, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading…

3 hours ago

Fibe empowers 2 lakh individuals to upskill through its financing solution, signs its 500th partnership with JAIN Online to expand access to affordable higher education

MUMBAI, India, Sept. 1, 2025 /PRNewswire/ -- Fibe, India's leading digital lending platform, partners with…

7 hours ago

APsystems Named Most Bankable Inverter Company Worldwide by Sinovoltaics

JIAXING, China, Amsterdam and AUSTIN, Texas, Sept. 1, 2025 /PRNewswire/ -- APsystems, a global leader…

7 hours ago

StockGro Launches Stoxo: India’s First Stock Market AI Research Platform That Turns Confusion into Conviction

BENGALURU, India, Sept. 1, 2025 /PRNewswire/ -- StockGro, India's leading investment advisory and knowledge platform, today…

8 hours ago

Vantage Marks Strong Presence at Cripto Latin Fest 2025 in Medelln

PORT VILA, Vanuatu, Sept. 1, 2025 /PRNewswire/ -- Vantage Markets proudly participated as a sponsor at…

8 hours ago